HEALIUS LIMITED (HLS)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

HLS

HLS - HEALIUS LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 4.06
Index: ASX300 | ALL-ORDS

Healius, formerly Primary Health Care, is an Australian provider of Pathology, Diagnostic and Day Hospital services. It has been listed since 1998.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.795

10 Sep
2025

-0.015

OPEN

$0.80

-1.85%

HIGH

$0.81

2,348,677

LOW

$0.79

TARGET
$0.84 5.7% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . DOC . EBO . IDX . M7T . MDR . MPL . MVF . NHF . PSQ . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
HLS: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx - 72.5 3.3 xxx
DPS (cps) xxx 41.3 0.5 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A - 98.8% xxx
PE Ratio xxx N/A 24.3 xxx
Dividend Yield xxx N/A 0.6% xxx
Div Pay Ratio(%) xxx N/A 15.4% xxx

Dividend yield today if purchased 3 years ago: 11.16%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 52.28

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 07/09 - ex-div 6c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-72.5
DPS All xxxxxxxxxxxxxxx41.3
Sales/Revenue xxxxxxxxxxxxxxx1,344.2 M
Book Value Per Share xxxxxxxxxxxxxxx81.0
Net Operating Cash Flow xxxxxxxxxxxxxxx262.7 M
Net Profit Margin xxxxxxxxxxxxxxx-41.88 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-69.14 %
Return on Invested Capital xxxxxxxxxxxxxxx-30.55 %
Return on Assets xxxxxxxxxxxxxxx-23.66 %
Return on Equity xxxxxxxxxxxxxxx-69.14 %
Return on Total Capital xxxxxxxxxxxxxxx0.01 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-103.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx181 M
Long Term Debt xxxxxxxxxxxxxxx731 M
Total Debt xxxxxxxxxxxxxxx912 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx57 M
Price To Book Value xxxxxxxxxxxxxxx0.97

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx65.9 M
Capex % of Sales xxxxxxxxxxxxxxx4.90 %
Cost of Goods Sold xxxxxxxxxxxxxxx1,124 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx220 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx2 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

22/08/2025

3

Neutral

$0.85

6.92%

Citi assesses Healius' FY25 result as consistent with its expectations. Underlying EBIT of $17.1m was close to the consensus of $17.5m.

Revenue was up 5.7%, and for FY26 the company guided to revenue growth in line with 2H25 which is around 5%. FY27 EBIT margin target of high single digit was maintained, though consensus is still at 4.2%.

Maintenance capex guidance for FY26 was similar to FY25 at -$16m. No final dividend was declared.

Neutral. Target price 85c.

Ord Minnett

xx/xx/xxxx

-1

xx xxxxxx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

xx/xx/xxxx

3

xxxxxx xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Jarden

26/08/2025

4

Underweight

$0.81

1.89%

Healius' FY25 EBIT of $17.1m met consensus but fell short of Jarden's forecast of $20.7m. Pathology EBIT margin worsened by -110bps y/y in 2H25 but this was expected.

Still, the broker took comfort from Pathology margin improvement in 2H to 3.6% from 0.6% in 1H. The company guided to 5% revenue growth in FY26 and while the broker upgraded its forecast, it is not convinced 5% growth will be achieved.

The bigger concern was net cash position which came in at $57.2m vs estimate of $196m, and the broker could only explain -$65m of the variance. 

Overall, FY26 EBIT forecast trimmed by -1.2% but FY27 lifted by 0.2%.

Underweight. Target rises to 81c from 79c on earnings revisions, roll-forward and lower risk-free rates.

FORECAST
Jarden forecasts a full year FY26 dividend of 0.00 cents and EPS of 1.30 cents.
Jarden forecasts a full year FY27 dividend of 1.70 cents and EPS of 3.00 cents.
Access Extra Coverage Research History >

HLS STOCK CHART

FNArena News on HLS

1
Rudi’s View: US Equities, CSL, Macquarie Technology, Xero & More

Sep 11 2025 - Rudi's View
2
Rudi’s View: August Results; Standouts, Turnarounds, Failures & Misfits

Sep 10 2025 - Rudi's View
3
Next Week At A Glance – 8-12 Sep 2025

Sep 05 2025 - Weekly Reports
4
Rudi’s View: Catalyst Metals, Dexus, Neuren, Stockland, ResMed & More

Sep 04 2025 - Rudi's View
5
Australian Broker Call *Extra* Edition – Aug 27, 2025

Aug 27 2025 - Daily Market Reports

Latest Healthcare services News

1
Better Times Ahead For Sonic Healthcare?

Jun 20 2025 - Australia
2
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
3
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
4
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
5
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
6
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
7
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
8
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
9
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
10
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps